demonstrated that the HER2 (2+) status is an unfavorable prognostic factor for the survival of patients with HR (+) BC, while the authors believed that the impact of anti-HER2 therapy in this group of patients should be evaluated (13). Here, ERBB2 is linked to breast cancer.